SpineGuard Reports 2020 Revenue
Regulatory News:
SpineGuard (Paris:ALSGD) (FR0011464452 ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, reported today its full-year 2020 revenue.
Pierre Jérôme, Chairman, CEO and co-founder of SpineGuard, said: The resurgence of the pandemic in the fourth quarter, particularly in the United States, once again led to postponements of non-urgent surgeries. This affected SpineGuard s revenue, along with many other medtech companies whose sales depend on surgery volume. In this context, our double-digit growth outside the United States is very encouraging knowing that the vaccination campaigns are now ramping up and that we are counting on the forthcoming US-FDA approval of the DSG Connect interface. Our financial discipline and tight control of our spending enabled us to remain close to operating EBIT breakeven, despite the health crisis, a
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
on December 16 2020 3:45 AM
The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers.
MELBOURNE, Australia & PARIS & BOSTON (BUSINESS WIRE) Regulatory News:
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a
biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY)
(Euronext: MKEA, ‘Mauna Kea’) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology.